Medifacts has been a centralized cardiovascular safety provider to the pharmaceutical and biotech industry since 1985, giving 25 years of proven experience. In addition, Medifacts has operated a full service core lab in Europe since 1992 and in Asia since 1998. Medifacts' prominent features and services include global presence, best in class technologies, and scientific leadership.  Medifacts’ key drivers are best in class Science, Service, and Technology.

Medifacts has earned a top position within the Core Lab industry by focusing on client needs and designing products, services and solutions to meet that need. Medifacts excels at customized service offerings, technologies and providing ‘high-touch’ service levels, both guiding our sponsors through the process, and taking guidance in order to provide the best fit to those needs. 

Medifacts International’s primary mission is to support the acquisition of data necessary to determine the safety and/or efficacy of drugs or devices involved in clinical trials. Medifacts has been instrumental in shaping the industry by setting standards of quality and unsurpassed service.

Today, as cardiovascular experts with international reach, Medifacts continues to lead the industry by upholding this standard of excellence.

 


 

2007
Medifacts divests in CRO division
Medifacts becomes one of the top 3 Cardiac Core Labs in the world
Introduction of Telemedicine Services

 
2006
Medifacts becomes one of the top 5 Cardiac Core Labs in the world.

 
2004

Medifacts launches its innovative WebHeart® platform for digital collection, interpretation, analysis and management of ECGs.

 

2002

All affiliates are consolidated under the name Medifacts International.


1998

Asian office opens in Shanghai, China. Our Asian office organizes the first pharmaceutical training course in China on ICH GCP guidelines.

 
1994
Medifacts' Core Laboratory Services is selected as a Collaborating Principal Investigator with the Division of Cardio-Renal Drug Products of the FDA under a Cooperative Research and Development Agreement (CRADA). The CRADA supports research in the analysis of ambulatory blood pressure data from subjects enrolled in placebo-controlled clinical trials.

 
1993
Medifacts' German office opens its doors in Cologne offering comprehensive service in Eastern and Western Europe.


1985
Medifacts is founded and is dedicated to providing 24-hour ambulatory blood pressure monitoring (ABPM). Core Laboratory Services quickly expands to include ECG and Holter monitoring services.